Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants
- Authors
- Lee, Min-Soo
- Issue Date
- Aug-2007
- Publisher
- PROUS SCIENCE, SAU-THOMSON REUTERS
- Citation
- DRUGS OF TODAY, v.43, no.8, pp 569 - 581
- Pages
- 13
- Indexed
- SCIE
SCOPUS
- Journal Title
- DRUGS OF TODAY
- Volume
- 43
- Number
- 8
- Start Page
- 569
- End Page
- 581
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/35872
- DOI
- 10.1358/dot.2007.43.8.1130447
- ISSN
- 1699-3993
1699-4019
- Abstract
- While pharmacological treatment of major depressive disorder with antidepressants continues to improve, responses remain poor in 30-50% of patients, with many patients discontinuing their medication due to distressing side effects. Drug response can be influenced by genetic factors and several physiological and environmental factors, including age, renal and liver function, nutritional status, smoking and alcohol consumption. In particular, genetic factors can be considered to contribute to antidepressant response. Genetic differences in response to antidepressants may be due to variants that affect the function of genes involved in both pharmacolkinetics and pharmacodynamics. Genetic variants affecting the metabolism of antidepressants may change pharmacokinetic factors, and polymorphisms that affect the functionof receptors and signal transduction molecules may alter pharmacodynamics. Both pharmacokinetic and pharmacodynamic change can affect the efficacy and side effects of antidepressants. (c) 2007 Prous Science. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Psychiatry > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.